Checkpoint Inhibitors No Less Safe With Radiation

Share this content:
Checkpoint Inhibitors No Less Safe With Radiation
Checkpoint Inhibitors No Less Safe With Radiation

FRIDAY, Sept. 29, 2017 (HealthDay News) -- Immune-related adverse events (IRAEs), including pneumonitis, are not more common in patients with metastatic lung cancer who receive both immune checkpoint inhibitors (CPIs) and thoracic radiotherapy (TRT), according to a research letter published online Sept. 28 in JAMA Oncology.

William L. Hwang, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues retrospectively studied 164 patients with metastatic lung cancer treated with programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibitors between 2013 and 2016.

The researchers found that rates of grade 2 or higher IRAEs, all-grade pneumonitis, and grade 2 or higher pneumonitis were not significantly different between patients receiving and not receiving TRT. None of the 16 patients who received TRT between CPI cycles or after CPI or had more than one course of TRT developed symptomatic pneumonitis. All-cause mortality was significantly lower in patients with grade 2 or higher IRAEs (HR, 0.45) and in those treated with fewer chemotherapy lines (HR, 1.21). There was reduced all-cause mortality with TRT, although the reduction was not significant.

"Pending prospective validation, our results suggest that TRT does not significantly increase the risk of symptomatic IRAEs, including pneumonitis, compared with CPIs alone," conclude the authors.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »